Last reviewed · How we verify

Bupivacaine Liposome Injection R preparation

Jiangsu HengRui Medicine Co., Ltd. · Phase 1 active Small molecule

Bupivacaine Liposome Injection R preparation is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 1 development. Also known as: EXPAREL®.

At a glance

Generic nameBupivacaine Liposome Injection R preparation
Also known asEXPAREL®
SponsorJiangsu HengRui Medicine Co., Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine Liposome Injection R preparation

What is Bupivacaine Liposome Injection R preparation?

Bupivacaine Liposome Injection R preparation is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd..

Who makes Bupivacaine Liposome Injection R preparation?

Bupivacaine Liposome Injection R preparation is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).

Is Bupivacaine Liposome Injection R preparation also known as anything else?

Bupivacaine Liposome Injection R preparation is also known as EXPAREL®.

What development phase is Bupivacaine Liposome Injection R preparation in?

Bupivacaine Liposome Injection R preparation is in Phase 1.

Related